Absci Corp (ABSI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Absci Corp stock (ABSI) is currently trading at $3.01. Absci Corp PS ratio (Price-to-Sales) is 158.12. Analyst consensus price target for ABSI is $8.05. WallStSmart rates ABSI as Sell.
- ABSI PE ratio analysis and historical PE chart
- ABSI PS ratio (Price-to-Sales) history and trend
- ABSI intrinsic value — DCF, Graham Number, EPV models
- ABSI stock price prediction 2025 2026 2027 2028 2029 2030
- ABSI fair value vs current price
- ABSI insider transactions and insider buying
- Is ABSI undervalued or overvalued?
- Absci Corp financial analysis — revenue, earnings, cash flow
- ABSI Piotroski F-Score and Altman Z-Score
- ABSI analyst price target and Smart Rating
Absci Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Absci Corp (ABSI) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Absci Corp (ABSI) Key Strengths (1)
77.69% of shares held by major funds and institutions
Supporting Valuation Data
Absci Corp (ABSI) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -77.80%, a shrinking business
Very expensive at 158.1x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Absci Corp (ABSI) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (158.12), Price/Book (2.12) suggest expensive pricing. Growth concerns include Revenue Growth at -77.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -55.70%, Operating Margin at -7977.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -55.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -77.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABSI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABSI's Price-to-Sales ratio of 158.12x sits near its historical average of 143.18x (81th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 82% below its historical high of 895.94x set in Jul 2021, and 395% above its historical low of 31.92x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~89.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Absci Corp (ABSI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Absci Corp operates as a stable business with moderate growth and solid fundamentals. Revenue reached 3M with 78% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 9M in cash.
Spending 684% of revenue (19M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 78% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -26M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.13, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Absci Corp.
Bottom Line
Absci Corp offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Absci Corp(ABSI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Absci Corp (ABSI) is a pioneering biotechnology company revolutionizing drug discovery through its state-of-the-art AI-driven biology platform. Focused on the rapid generation of high-quality proteins and therapeutic candidates, Absci significantly accelerates traditional development timelines while lowering associated costs. The company is dedicated to transforming the biopharmaceutical landscape by equipping partners with innovative tools to develop and manufacture next-generation therapies with unparalleled efficiency and precision. With a robust pipeline of collaborations and proprietary initiatives, Absci is strategically positioned to drive significant advancements in disease treatment and modern drug development practices.